2024年IBD研究中的挑战:精准医学
Sana Syed1,2, Brigid S Boland3, Lauren T Bourke4
1Department of Pediatrics, University of Virginia, Charlottesville, VA, USA.
Inflammatory bowel diseases
|May 23, 2024
概括
精准医学通过解决生物标志物发现和验证方面的研究缺口,推动了炎症性肠病 (IBD) 护理. 这种以患者为中心的方法旨在改善IBD患者的治疗选择和疾病管理.
科学领域:
- 生物医学研究生物医学研究
- 翻译科学 翻译科学
- 精准医学是一门精准的医学.
背景情况:
- 炎症性肠病 (IBD) 研究面临着重大差距,阻碍了个性化治疗策略.
- 在IBD研究2024年的挑战文件确定了进步的关键领域,包括精密医学.
- 以前的研究工作,如2019年IBD研究中的挑战,为当前的优先事项奠定了基础.
研究的目的:
- 提供关于IBD当前研究缺口的全面概述.
- 提出可行的策略来解决这些差距,重点关注精准医学.
- 通过以患者为中心的研究,在IBD患者护理中推进拦截,缓解和恢复.
主要方法:
- 来自科学家,临床医生,患者和资助者的多学科投入.
- 确定生物标志物发现,验证,数据利用和监管途径的研究缺口.
- 为生物标志物验证和临床实施开发可操作的方法.
主要成果:
- 在预测疾病进展和通过生物标志物选择最佳治疗方面发现了关键的研究缺口.
- 在利用患者生物样本,临床数据和先进分析技术方面存在挑战.
- 监管和付款人的障碍阻碍了IBD生物标志物的临床采用.
结论:
- 对候选生物标志物的彻底验证对于IBD的精准医学至关重要.
- 使用先进的数据生成和分析工具至关重要.
- 早期建立跨学科团队可以克服生物标志物实施的监管障碍.
更多相关视频
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Inflammatory Bowel Disease I: Ulcerative Colitis
165
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
165
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inflammatory Bowel Disease II: Crohn's Disease
217
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
217
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131


